Abstract The causative agent of coronavirus disease (COVID-19) has omnipresent worldwide spread, infecting more than two million people and causing over 150,000 deaths worldwide, resulting in devastating global health emergencies. Extreme acute respiratory syndrome 2 (sarkozydia) Early in its global expansion, the COVI-19 pandemic was further fuelled by insufficient access to laboratory research. Real-time RT-PCR Diagnostic Panel was the first test obtained from the US Food and Drug Administration on February 4, 2020, by the Centers for Disease Control and Prevention (CDC) 2019–Novel Coronavirus (2019–nCoV)1–3 . This test was therefore introduced by a significant number of public health and clinical labs in the USA. Many manufacturers of commercial instruments then obtained EUAs for molecular SARS-CoV-2 identification. However, producers also assign reagents. Many of the clinical laboratories have therefore used several platforms to satisfy research criteria.